- Home
- AEVA vs ALT Comparison
AEVA vs ALT Comparison
Compare AEVA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- ALT
- Stock Information
- Founded
- AEVA 2019
- ALT 1997
- Country
- AEVA United States
- ALT United States
- Employees
- AEVA N/A
- ALT N/A
- Industry
- AEVA Auto Parts:O.E.M.
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- ALT Health Care
- Exchange
- AEVA Nasdaq
- ALT Nasdaq
- Market Cap
- AEVA 560.5M
- ALT 472.3M
- IPO Year
- AEVA N/A
- ALT N/A
- Fundamental
- Price
- AEVA $17.32
- ALT $5.30
- Analyst Decision
- AEVA Buy
- ALT Strong Buy
- Analyst Count
- AEVA 6
- ALT 7
- Target Price
- AEVA $13.60
- ALT $21.00
- AVG Volume (30 Days)
- AEVA 2.8M
- ALT 2.3M
- Earning Date
- AEVA 05-14-2025
- ALT 05-13-2025
- Dividend Yield
- AEVA N/A
- ALT N/A
- EPS Growth
- AEVA N/A
- ALT N/A
- EPS
- AEVA N/A
- ALT N/A
- Revenue
- AEVA $10,326,000.00
- ALT $20,000.00
- Revenue This Year
- AEVA $80.29
- ALT $4,108.32
- Revenue Next Year
- AEVA $196.79
- ALT $3,900.06
- P/E Ratio
- AEVA N/A
- ALT N/A
- Revenue Growth
- AEVA 95.90
- ALT N/A
- 52 Week Low
- AEVA $2.20
- ALT $3.55
- 52 Week High
- AEVA $18.74
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- AEVA 68.05
- ALT 46.70
- Support Level
- AEVA $13.74
- ALT $5.38
- Resistance Level
- AEVA $18.69
- ALT $5.74
- Average True Range (ATR)
- AEVA 1.90
- ALT 0.34
- MACD
- AEVA 0.08
- ALT -0.06
- Stochastic Oscillator
- AEVA 77.39
- ALT 15.31
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.